PE-Labeled Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag (Nanodisc) (Site-specific conjugation)

사용자 리뷰
제품 번호/규격
가격
Availability
수량
CL2-HP2D3-25tests
$1470.00
In Stock - Delivery in 1-2 business days
CL2-HP2D3-200tests
$7320.00
In Stock - Delivery in 1-2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    Claudin-18.2, CLDN18, Claudin-18

  • Source

    Nanodisc PE-Labeled Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag (CL2-HP2D3) is produced via site-specific conjugation of PE to Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag under optimal conditions with a proprietary technology. Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 200 (Accession # P56856-2). In the region Met 1 - Ala 200, the amino acid sequences of Human and Cynomolgus Claudin-18.2 are identical.

    Predicted N-terminus: Met

    Request for sequence

  • Molecular Characterization

    Claudin-18.2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus and a Flag tag at the C-terminus. The protein has a calculated MW of 26.8 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-HP1E3) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.

    2. Synthesis Process

      Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • Bioactivity-ELISA

     Claudin-18.2 ELISA

    Immobilized PE-Labeled Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag (Cat. No. CL2-HP2D3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 (Cat. No. CL2-M34) with a linear range of 0.0003-0.078 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-Flow Cytometry

     Claudin-18.2 FACS

    5e5 of Anti-Claudin18.2 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human / Cynomolgus Claudin18.2 Protein, His,Flag Tag (Cat. No. CL2-HP2D3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

A tight junction protein normally confined to gastric mucosa but exposed on tumor cell surfaces during malignant transformation. It is a premier target in gastric and pancreatic adenocarcinoma, with the monoclonal antibody zolbetuximab demonstrating significant survival benefit in CLDN18.2-positive advanced disease.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Claudin-18 splice variant 2

  • 카테고리:

  • 상장 의약품 수:

    1 상세

  • 임상 의약품 수:

    82 상세

  • 최고 개발 단계:

    Approved

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경